Neuraxis, Inc. reported $1.6M revenue in Q1 2026, an 80% increase. Learn about strategic initiatives and future outlook.

Key Takeaways

• Revenue in Q1 2026 reached $1.6 million, an 80% increase from $896,000 in Q1 2025.
• Average selling price (ASP) of IV STEM devices rose 33% to $1,017 per unit.
• The company saw a significant increase in the number of ordering accounts, rising to 66 from 56 year-over-year.
• Operating loss was reduced to $1.7 million, a 24% decrease compared to $2.3 million in Q1 2025.
• Neuraxis is focused on expanding payer coverage and enhancing operational capacity in children's hospitals.

Financial Performance

Neuraxis, Inc. reported an impressive financial performance for the first quarter of fiscal year 2026. The company’s revenue surged to $1.6 million, marking an 80% increase from $896,000 in the same quarter of the previous year. This quarter represents the highest quarterly revenue in the company's history, largely attributed to the effective launch of the Category 1 CPT code for IV STEM procedures on January 1, 2026.

The strong performance is further underscored by a 33% increase in the average selling price (ASP) of the IV STEM devices, which rose to $1,017 from $766 in Q1 2025. This shift towards higher-margin payer segments indicates a favorable change in the reimbursement landscape as more healthcare providers transitioned from discount programs to full reimbursement channels.

Gross margin also improved, reaching 86.4%, compared to 84.4% in the same quarter last year, fueled by a more favorable payer mix. The company's operating loss narrowed to $1.7 million, down 24% from the previous year, reflecting effective cost management and revenue growth.

Strategic Initiatives

In Q1 2026, Neuraxis identified several key areas driving its growth and strategic outlook:

• Insurance Coverage and Payer Progress: The company emphasized that securing written medical policies remains essential for scalable growth. Neuraxis aims to enhance its payer strategy to expand coverage and improve operational efficiency for healthcare providers.
• Key Performance Indicators (KPIs): Management highlighted the introduction of a KPI framework to better explain performance and future growth potential. Notably, the approval rate for prior authorizations improved significantly to 32% in Q1 2026, up from 12% throughout 2025.
• Commercialization Focus: Neuraxis has shifted from access creation to execution, primarily targeting children's hospitals where the demand for IV STEM is strong. The company is aligning its commercial structure to maximize opportunities in high-potential markets.
• Hiring and Leadership Changes: The organization is bolstering its commercial leadership with dedicated vice presidents for sales and marketing to enhance coordination and execution.
• Veterans Affairs (VA) Opportunity: The company secured a Federal Supply Schedule contract, which opens a pathway to the VA healthcare system, potentially reaching 7 million active patients annually. Early indications suggest that multiple VA facilities are beginning to place orders, which could represent a significant growth avenue.

Future Outlook

Looking ahead, Neuraxis maintains a positive outlook for fiscal year 2026. Management expects ongoing revenue growth driven by expanded payer coverage and improved operational execution. The recent success in Q1 has provided the company with a clearer understanding of the drivers and constraints of adoption, enabling a more focused approach to enhancing medical policy coverage and operational efficiency.

Management has set ambitious targets for new account acquisition while ensuring that existing accounts are well supported with the necessary resources for successful IV STEM utilization. The emphasis will be on achieving depth in existing high-potential accounts while cautiously expanding into new markets.

Neuraxis also anticipates that as additional payer policies come online, there will be an uptick in revenue and gross margin due to the favorable reimbursement environment. The company is strategically preparing to leverage these developments to sustain its growth trajectory.

In conclusion, Neuraxis, Inc. is well-positioned for sustained growth, backed by a robust first-quarter performance and clear strategic initiatives focused on payer engagement, operational excellence, and market expansion. As the company continues to navigate the evolving healthcare landscape, its commitment to addressing unmet medical needs remains a driving force behind its operational strategies.

This analysis is based on public earnings call materials and is not investment advice.